An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma

British Journal of Cancer

Volumn 76, Issue 7, 1997, Pages 836-844

  Vora, A R ^a   Rodgers, S ^b   Parker, A J ^c   Start, R ^b   Rees, R C ^d   Murray, A K ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

Cancer immunotherapy; Head and neck squamous cell carcinoma; HLA; ICAM 1; Immunohistochemistry; TAP

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN P53; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0030865982     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.472     Document Type: Article

References (42)

1. Boon T, Gajewski F and Coulie PG (1995) From defined humun tumour antigens to effective immunisation? Immunol Today 16: 334-335
2. Chikamatsu K, Eura M, Matsuoka H, Nurakumi H and Fukiage T (1994) The role of major histocompatibility complex expression on head and neck cancer cells in the induction of autologous cytotoxic T-lymphocytes. Cancer Immunol Immunother 38: 358-364
3. Cromme FV, Airey J, Heemels M-T, Ploegh HL, Keating PJ, Stern PL, Meijer CJLM and Walboomers JMM (1994) Loss of transporter protein, encoded by TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179: 335-340
4. Ellis JRM, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS and Stern PL (1995) The association of an HPV 16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Med 1: 464-470
5. Esteban F, Concha A, Huelin C, Pérez-Ayala M, Pedrinaci S, Ruiz-Cabbello F and Garrido F (1989) Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx. Int J Cancer 43: 436-442
6. Farrar MA and Schreiber RD (1993) The molecular cell biology of interferon γ and its receptor. Annu Rev Immunol 11: 571-611
7. Ferrone S and Marincola FM (1995) Loss of HLA class 1 antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16: 487-494
8. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F and Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14: 491-499
9. Garrido F, Cabrera T, Lopez-Nevot MA and Ruiz-Carbello F (1995) HLA class I antigens in human tumors. Adv Cancer Res 67: 155-195
10. Graubert TA and Lev TJ (1996) How do lymphocytes kill tumour cells? Clin Cancer Res 2: 785-789
11. WAF1/cip1, gadd 45, cyclins, cyclin-dependent kinases and PCNA in oral cancer. Int J Oncol 8: 21-28
12. Hald J, Rasmussen N and Claesson MH (1995) Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother 39: 383-390
13. Honma S, Tsukada S, Honda S, Nakamura M, Takakuma K, Maruhashi T, Kodama S, Kanazawa K, Takahashi T and Tanaka T (1994) Biological-clinical significance of selective loss of HLA-class I allelic product expression in squamous cell carcinoma of the uterine cervix. Int J Cancer 57: 650-655
14. Houck JR, Sexton M and Zajdel G (1990) HLA class I and class II antigen expression on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 116: 1181-1185
15. Ioachim H (1990) The opportunistic tumours of immune deficiency. Adv Cancer Res 54: 301-317
16. Irvine KR and Restifo NP (1995) The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol 6: 337-347
17. Ishii H, Gochi A and Orita K (1994) Enhancement of cell surface ICAM-I and HLA class I antigens in human gastric cancer cell lines by IFN-γ. Acta Med Okayama 48: 73-79
18. Janeway Jr. CA and Travers P (1994) Immunobiology: the Immune System in Health and Disease. Current Biology: London
19. June CH, Bluestone JA, Nadler LM and Thompson CB (1944) The B7 and CD28 receptor families. Immunol Today 15: 321-331
20. Kaklamanis L, Leek R, Koukourakis M, Gatter KC and Harris AL (1995) Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. Cancer Res 55: 5191-5194
21. Keating PJ, Cromme FV, Duggan-Keen M, Snijders PJF, Walboomers JMM, Hunter RD, Dyer PA and Stern PL (1995) Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer 72: 405-411
22. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL and Gatter KC (1946) Loss of antigen-presenting molecules (MHC class 1 and TAP-1) in lung cancer. Br J Cancer 73: 148-153
23. Lebmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T and Coulie PG (1995) Differences in the antigens recognised by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25: 340-347
24. Maeurer MJ, Gollin SM, Storkus WJ, Swaney W, Karbach J, Martin D, Castelli C, Salter R, Knuth A and Lotze MJ (1996) Tumour escape from immune recognition: Loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 2: 641-652
25. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Hermann J, Coulie PG and Boon T (1995) Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGH-3. Int J Cancer 63: 883-885
26. Matsushita K, Takenouchi T, Kobayashi S, Hayashi H, Okuyama K, Ochiai T, Mikata A and Isono K (1996) HLA-DR antigen expression on colorectal carcinomas: influence of expression by IFNγ in situ, and its association with tumour progression. Br J Cancer 73: 644-648
27. Mattijsen V, De Mulder PHM, Schalkwijk L, Manni JJ, Van't Hof-Grootenboer B and Ruiter DJ (1991) HLA antigen expression in routinely processed head and neck squamous cell carcinoma primary lesions of different sites. Int J Cancer Suppl. 6: 95-100
28. Momburg F, Ziegler A, Harpprecht J, Moller P, Moldenhaur G and Hammerling GT (1989) Selective loss of HLA-A or HLA-B antigen expression in colon carcinoma. J Immunol 142: 352-358
29. Mulcahy KA, Rimoldi D, Brasseur F, Rodgers S, Lienard D, Marchand M, Rennie IG, Murray AK, McIntyre CA, Platts KE, Leyvraz S, Boon T and Rees RC (1996) Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer 66: 738-742
30. Neefjes JJ and Ploegh HL (1992) Intracellular transport of MHC class II molecules. Immunol Today 13: 179-183
31. Pardoll DM (1993) Cancer vaccines. Immunol Today 14: 310-316
32. Parham P and Ohta T (1996) Population biology of antigen presentation by MHC class I molecules. Science 272: 67-74
33. Restifo NP and Wunderlich JR (1995) Biology of cellular immune responses. In Biologic Therapy of Cancer, 2nd edn. De Vita Jr. VT. Hellman S and Rosenberg SA. (eds), pp. 3-37. JB Lippincott: Philadelphia
34. Rivoltini L, Barracchin KC, Viggiano V, Kawakami Y, Smith A, Mixon A, Restifo NP, Topalian SL, Simonis TB, Rosenberg SA and Marincola FM (1995) Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T-lymphocytes. Cancer Res 55: 3149-3157
35. Samukawa T (1993) Expression of HLA-DR antigen on head and neck carcinomas - immunohistological study (Japanese). Nippon-Jibünkoka-Gattai-Kaiho 96: 88-97
36. Scher RL, Koch WM and Richtsmeier WJ (1993) Induction of the intercellular adhesion molecule (ICAM-1) on squamous cell carcinoma by interferon gamma. Arch Otolaryngol Head Neck Surg 119: 432-438
37. Seliger B, Höhne A, Knuth A, Bernhard H, Meyer T, Tampe R, Momburg F and Huber C (1996) Analysis of the major histocompatibility class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 56: 1756-1760
38. Springer TA (1990) Adhesion receptors of the immune system. Nature 346: 425-433
39. Van de Stolpe A and Van der Saag PT (1996) Intercellular adhesion molecule-1. J Mol Med 74: 13-33
40. Vánky F, Hising C, Sjöwall K, Larsson B, Rodriguez L, Orre L and Klein E (1995) Immunogeneity and immunosensitivity of ex vivo human carcinomas: interferon γ and tumour necrosis factor α treatment of tumour cells potentiates their interaction with autologous blood lymphocytes. Cancer Immunol Immunother 41: 217-226
41. Wiedenfeld EA, Fernandez-Vina M, Berzofsky JA and Carbone DP (1994) Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. Cancer Res 94: 1175-1177
42. York IA and Rock KL (1996) Antigen processing and presentation by the class I major histocompatibity complex. Annu Rev Immunol 14: 369-396